Dyadic International Inc (DYAI): R&D Expense
$2.15M
Year ended 2025-12-31
$1.84M
Trailing 12 months to 2026-06-30
-21.8%
3-year compound annual growth
-11.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.15M | +5.4% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $2.04M | -38.0% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $3.30M | -26.7% | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | $4.50M | -46.4% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $8.39M | +117.0% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $3.87M | +25.3% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $3.09M | +46.9% | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | $2.10M | +19.0% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $1.77M | n/a | 2019-03-27, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Dyadic International Inc (DYAI) | 2025-12-31 | $2.15M | +5.4% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $29.36M | +39.0% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $284.81M | -8.2% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $116.64M | +42.1% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $69.45M | -1.2% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $39.75M | +23.7% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $160.64M | +3.4% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $69.30M | -21.8% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $100.0K | -39.0% |
Compare DYAI, SRZN, CRSP, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗